Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( <scp>LIGHT</scp> 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
Efsubaglutide Alfa demonstrated significant weight-loss efficacy, metabolic improvements, and a preferable tolerability and safety profile, supporting further clinical development for obesity and related metabolic disorders.
Authors
- Wei Hu (ORCID: https://orcid.org/0000-0001-9332-9670)
- Mingxia Yuan (ORCID: https://orcid.org/0009-0004-4597-0403)
- Fei Gao (ORCID: https://orcid.org/0009-0005-1647-2146)
- WEIPING JIA
- XIAOLIN DONG
- Ruihua Dong
- Danfeng Peng
- Jingcheng Chen (ORCID: https://orcid.org/0000-0002-1199-9599)
- Yuqian Bao
- Yulong Xu
- Jian Zhou
- Nianrong Mi
- Qinghua Wang
Institutions
- Capital Medical University (CN)
- Jinan Central Hospital (CN)
- Buchang Pharma (China) (CN)
- Shanghai Sixth People's Hospital (CN)
- Beijing Friendship Hospital (CN)
- Huashan Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1111/dom.70429
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00